



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: November 7<sup>th</sup>, 2018*

**Quantity Limit Name:** Olumiant (baricitinib)

**Products Affected:** Olumiant (baricitinib)

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

Olumiant (baricitinib) 2mg:      30 tablets per 30 days

**References:**

1. Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2018

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	11/7/2018

Last Res. 11/7/2018